TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29953575

Group type: EXPERIMENTAL
Intervention: Hypertonic saline-hydroxyethyl starch (HS-HES) solution
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 50
Study: 27673385

Group type: EXPERIMENTAL
Intervention: Epinephrine (0.1 to 0.2 to 0.3 μg/kg/min)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dopamine (10 to 15 to 20 μg/kg/min)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dopamine
Number of subjects: 60
Study: 25670057

Group type: EXPERIMENTAL
Intervention: Optimax™ bioactive stent (BAS)
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Synergy™ drug-eluting stent (EES)
Number of subjects: 1800
Study: 23766396

Group type: EXPERIMENTAL
Intervention: Alberta Infant Motor Scale (AIMS)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Psychomotor Developmental Index (PDI) of the Bayley Scales of Infant Development‐Dutch Second Edition (BSID‐II‐NL)
Number of subjects: 116
Study: 21044314

Group type: EXPERIMENTAL
Intervention: 6-month physical activity stimulation program (lifestyle intervention and fitness training)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Regular pediatric physiotherapy (control group)
Number of subjects: 50
Study: 18362876

Group type: EXPERIMENTAL
Intervention: Print advertising for bipolar disorder study
Number of subjects: 526
Study: 17001402

Group type: EXPERIMENTAL
Intervention: Detailed educational information
Number of subjects: 75

Group type: COMPARATOR
Intervention: Basic information about the procedure
Number of subjects: 75
Study: 12437707

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no intrathecal morphine)
Number of subjects: 36
Study: 10357168

Group type: EXPERIMENTAL
Intervention: Individually tailored behavioural programme with telephone support from the therapist
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 7532382

Group type: EXPERIMENTAL
Intervention: Discharge instructions with illustrations (n = 54)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Discharge instructions without illustrations (n = 47)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Discharge instructions with illustrations among nonwhites (n = 51)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Discharge instructions with illustrations among patients with no more than a high school education (n = 71)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Discharge instructions with illustrations among women (n = 48)
Number of subjects: 101
Study: 1789096

Group type: EXPERIMENTAL
Intervention: Astigmatism treatment
Number of subjects: 238
Study: 7340895

Group type: EXPERIMENTAL
Intervention: Signaled running time task with a preparatory interval of 10, 15, or 20 sec.
Number of subjects: 16
Study: 30721572

Group type: EXPERIMENTAL
Intervention: Liraglutide 3 mg daily for 26 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Diet and exercise (energy restriction plus moderate-intensity exercise) for 26 weeks
Number of subjects: 30
Study: 27838115

Group type: EXPERIMENTAL
Intervention: Sevoflurane (2.5-4 percent) inhalation in Group S (n=7)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Propofol infusion (1-2mg·kg-1·min-1) in Group P (n=7)
Number of subjects: 14
Study: 26886026

Group type: EXPERIMENTAL
Intervention: Testing for herpes simplex virus type 2 (HSV-2)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Proposed plan to disclose HSV-2 test results to adolescents only
Number of subjects: 32

Group type: COMPARATOR
Intervention: Request for parental access to results
Number of subjects: 32
Study: 25087907

Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope
Number of subjects: 128

Group type: COMPARATOR
Intervention: McGrath(®) Series 5 videolaryngoscope
Number of subjects: 128
Study: 22776970

Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg daily
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 19734366

Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) at -40 mmHg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) at -40 mmHg in ischemic cardiomyopathy (ICM) patients
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cold pressor testing in ischemic cardiomyopathy (ICM) patients (n = 4)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lower body negative pressure (LBNP) at -40 mmHg in nonischemic or dilated cardiomyopathy (DCM) patients
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lower body negative pressure (LBNP) at -40 mmHg in normal (N) group
Number of subjects: 12
Study: 17466854

Group type: EXPERIMENTAL
Intervention: Group A (n = 20) received 20 mg/0.5 mL of methylprednisolone and 10 mg/0.5 mL of gentamicin injected into the posterior sub‐Tenon's space
Number of subjects: 40

Group type: COMPARATOR
Intervention: Group B (n = 20) received the same combination injected into the anterior sub‐Tenon's space
Number of subjects: 40
Study: 15754633

Group type: EXPERIMENTAL
Intervention: High voltage stimulation
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (pharmacological treatment only)
Number of subjects: 25
Study: 12105409

Group type: EXPERIMENTAL
Intervention: Lidocaine 2%
Number of subjects: 1893

Group type: EXPERIMENTAL
Intervention: Ropivacaine 1%
Number of subjects: 1893

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 1893
Study: 10102969

Group type: EXPERIMENTAL
Intervention: olsalazine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: mesalazine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Comparison of olsalazine and mesalazine
Number of subjects: 15
Study: 7586997

Group type: EXPERIMENTAL
Intervention: Med 15 (1.200 mg for 2 days, then 600 mg for 13 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Piroxicam (same dosage regimen as Med 15)
Number of subjects: 30
Study: 2251029

Group type: EXPERIMENTAL
Intervention: Human milk protein-enriched human milk
Number of subjects: 28

Group type: COMPARATOR
Intervention: Protein-unenriched human milk
Number of subjects: 28
Study: 6986027

Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg every six hours)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Antacid (Mylanta II, 30 ml every hour)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Cimetidine with antacid titration
Number of subjects: 75
Study: 30673108

Group type: EXPERIMENTAL
Intervention: Psoriasis incidence
Number of subjects: 14705

Group type: EXPERIMENTAL
Intervention: Lifetime prevalence of psoriasis
Number of subjects: 14705

Group type: EXPERIMENTAL
Intervention: Mortality rate among psoriasis patients
Number of subjects: 14705
Study: 27966574

Group type: EXPERIMENTAL
Intervention: Inulin (IN) 24g
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Resistant Starch (RS) 28.2g
Number of subjects: 25

Group type: COMPARATOR
Intervention: Glucose (GLU) 75g
Number of subjects: 25
Study: 25909567

Group type: COMPARATOR
Intervention: Any form of image guidance
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Augmented reality
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Always-on solid overlay
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Wire mesh and on-demand overlays
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Wire mesh and inverse realism overlays
Number of subjects: 50
Study: 23964752

Group type: EXPERIMENTAL
Intervention: DDEA 1.16% gel (2 g, 4x/day, for 5 days)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 72
Study: 21423115

Group type: EXPERIMENTAL
Intervention: Vasoactive, antioxidant treatment and neuromidin (15 mg in solution for 10 days, then 20 mg three times a day for 2 months)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vasoactive and antioxidant treatment
Number of subjects: 40
Study: 19684171

Group type: EXPERIMENTAL
Intervention: 20 g of spread with a target dose of 1 x 10(9) CFU of L. reuteri DSM 17938
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 20 g of spread with a target dose of 5 x 10(9) CFU of L. rhamnosus GG
Number of subjects: 42

Group type: COMPARATOR
Intervention: 20 g of placebo spread
Number of subjects: 42
Study: 17766284

Group type: EXPERIMENTAL
Intervention: Perindopril 8 mg/day
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 14604267

Group type: EXPERIMENTAL
Intervention: Genistein (54 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hormone replacement therapy
Number of subjects: 0
Study: 11020092

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Sertraline therapy
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Combination of exercise and sertraline
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Exercise during follow-up
Number of subjects: 156
Study: 9432270

Group type: EXPERIMENTAL
Intervention: Bovine pericardium patch angioplasty
Number of subjects: 52
Study: 1469180

Group type: EXPERIMENTAL
Intervention: Isoflurane (0.1‐0.6% in air‐oxygen mixture)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Midazolam (continuous infusion of 0.02‐0.20 mg/kg/h)
Number of subjects: 60
Study: 6325909

Group type: EXPERIMENTAL
Intervention: Live attenuated Oka/Merck varicella vaccine
Number of subjects: 956

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 956
Study: 3787660

Group type: COMPARATOR
Intervention: 0.00 ppm SO2
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 0.25 ppm SO2
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 0.50 ppm SO2
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 1.00 ppm SO2
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 2.00 ppm SO2
Number of subjects: 27
Study: 29190319

Group type: EXPERIMENTAL
Intervention: Pelvic radiotherapy (RT) with concurrent and adjuvant chemotherapy (two cycles of cisplatin 50 mg/m2 in weeks 1 and 4 of RT, followed by four cycles of carboplatin AUC5 and paclitaxel 175 mg/m2)
Number of subjects: 329

Group type: COMPARATOR
Intervention: Pathology review
Number of subjects: 329
Study: 27523919

Group type: EXPERIMENTAL
Intervention: Creatine (0.1g/kg/day of creatine + 0.1g/kg/day of maltodextrin)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (0.2g/kg/day of maltodextrin)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Drop-set resistance training
Number of subjects: 31
Study: 25687834

Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix (ADM) with autologous split‐thickness skin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (autogenous split‐thickness skin implant)
Number of subjects: 30
Study: 23370075

Group type: EXPERIMENTAL
Intervention: Gastroretentive gabapentin (G-GR) 1800 mg (600 mg AM/1200 mg PM) for 14 weeks
Number of subjects: 80
Study: 20389247

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Controlled Home Training (HT)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Prolonged Supervised Training (ST)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Preferred Training (PT)
Number of subjects: 69
Study: 19105823

Group type: EXPERIMENTAL
Intervention: Facilitation process of the complex intervention
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Case discussions between link workers and GPs
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Facilitators providing advice and manpower
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Development of IT systems
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Reviewing function of the intervention
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Case discussions and improved liaison at times of crisis
Number of subjects: 46
Study: 16880481

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo (matching)
Number of subjects: 174
Study: 12670814

Group type: EXPERIMENTAL
Intervention: PDA (personal digital assistant)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Paper-based method
Number of subjects: 1
Study: 10822898

Group type: EXPERIMENTAL
Intervention: Fluvastatin (80 mg/d)
Number of subjects: 26
Study: 8639297

Group type: EXPERIMENTAL
Intervention: Modified or classic radical neck dissection
Number of subjects: 159

Group type: COMPARATOR
Intervention: Conventional surgery and radiation
Number of subjects: 159
Study: 1323501

Group type: EXPERIMENTAL
Intervention: Ossein-hydroxyapatite compound (OHC) 6.46 g daily for 6 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no bone protective treatment)
Number of subjects: 20
Study: 6507131

Group type: EXPERIMENTAL
Intervention: iohexol
Number of subjects: 50

Group type: COMPARATOR
Intervention: metrizamide
Number of subjects: 50
Study: 31168851

Group type: EXPERIMENTAL
Intervention: Chronic Disease Self-Management Program (CDSMP)
Number of subjects: 1067
Study: 30197417

Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 470

Group type: COMPARATOR
Intervention: Everolimus
Number of subjects: 470
Study: 26659550

Group type: EXPERIMENTAL
Intervention: Lurasidone 20 mg/day
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Lurasidone 60 mg/day
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 24458316

Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT) patches
Number of subjects: 3094

Group type: COMPARATOR
Intervention: Self-help booklet or cessation website
Number of subjects: 3094

Group type: COMPARATOR
Intervention: Marijuana use and binge drinking
Number of subjects: 3094
Study: 23073480

Group type: EXPERIMENTAL
Intervention: Femtosecond laser flap creation
Number of subjects: 2

Group type: COMPARATOR
Intervention: Mechanical microkeratome flap creation
Number of subjects: 2
Study: 20056625

Group type: EXPERIMENTAL
Intervention: Low-fat dietary pattern (DM intervention)
Number of subjects: 1676
Study: 17884396

Group type: EXPERIMENTAL
Intervention: High dose rate brachytherapy as a boost after external beam chemoradiotherapy
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional preoperative chemoradiotherapy using a bolus 5-fluorouracil regimen
Number of subjects: 16
Study: 15609386

Group type: EXPERIMENTAL
Intervention: Clopidogrel and aspirin
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo and aspirin
Number of subjects: 132
Study: 12115017

Group type: EXPERIMENTAL
Intervention: 500 mg vitamin C
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 1000 mg vitamin C
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 2000 mg vitamin C
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control (no vitamin C)
Number of subjects: 54
Study: 11789184

Group type: EXPERIMENTAL
Intervention: Puerarin 400 mg per day intravenously dripping
Number of subjects: 30

Group type: COMPARATOR
Intervention: Mikebao 500 micrograms intramuscularly, once per day
Number of subjects: 30
Study: 9092223

Group type: EXPERIMENTAL
Intervention: Endarterectomy (n = 825)
Number of subjects: 1659

Group type: COMPARATOR
Intervention: Medical therapy (n = 834)
Number of subjects: 1659
Study: 1640952

Group type: EXPERIMENTAL
Intervention: Transcervical chorionic-villus sampling
Number of subjects: 3999

Group type: COMPARATOR
Intervention: Transabdominal chorionic-villus sampling
Number of subjects: 3999
Study: 6540129

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (i.v. IgG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral corticosteroids
Number of subjects: 0
Study: 30370686

Group type: EXPERIMENTAL
Intervention: Proximal metformin (1000 mg) + distal saline
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Distal metformin (1000 mg) + proximal saline
Number of subjects: 10

Group type: COMPARATOR
Intervention: Proximal + distal saline (control)
Number of subjects: 10
Study: 28524358

Group type: EXPERIMENTAL
Intervention: Yoga intervention (10-week program)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (no-treatment assessment-only)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Self-selected wait-list yoga group (n = 7)
Number of subjects: 51
Study: 27572070

Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg Q2W
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 25015544

Group type: EXPERIMENTAL
Intervention: Protease inhibitor monotherapy (darunavir/ritonavir or lopinavir/ritonavir)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Triple drug therapy (two nucleos(t)ides)
Number of subjects: 146
Study: 21573944

Group type: EXPERIMENTAL
Intervention: Adequate health literacy levels
Number of subjects: 722

Group type: COMPARATOR
Intervention: Inadequate/marginal functional health literacy
Number of subjects: 722
Study: 20397453

Group type: EXPERIMENTAL
Intervention: Acupuncture at 7-9 am
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Acupuncture at 3-5 pm
Number of subjects: 90

Group type: COMPARATOR
Intervention: Drug control group
Number of subjects: 90
Study: 18672987

Group type: EXPERIMENTAL
Intervention: Powered toothbrush
Number of subjects: 122

Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 122

Group type: COMPARATOR
Intervention: Manual toothbrush with floss
Number of subjects: 122
Study: 16351669

Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg
Number of subjects: 1215

Group type: COMPARATOR
Intervention: atorvastatin 10 mg
Number of subjects: 1215

Group type: COMPARATOR
Intervention: simvastatin 20 mg
Number of subjects: 1215

Group type: COMPARATOR
Intervention: pravastatin 40 mg
Number of subjects: 1215
Study: 14563515

Group type: EXPERIMENTAL
Intervention: Standard-dose chemotherapy with primary prophylaxis using hemopoietic growth factors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Innovative strategies in the use of hemopoietic growth factors
Number of subjects: 0
Study: 10473984

Group type: EXPERIMENTAL
Intervention: Intravesical capsaicin
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 7769318

Group type: EXPERIMENTAL
Intervention: Chloroquine (25 mg of base/kg during 3 days or 10 mg of base/kg in one dose) plus primaquine (10 mg/kg during 28 days or 2.5 mg/kg during 3 days)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Chloroquine plus placebo
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Halofantrine (24 mg base/kg in 12 h)
Number of subjects: 147
Study: 2182613

Group type: EXPERIMENTAL
Intervention: Phosphatidylcholine (lecithin) 20 g/day
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 311979

Group type: EXPERIMENTAL
Intervention: 150 mg Peptide-PABA
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 1 g Peptide-PABA
Number of subjects: 2
Study: 31599995

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention comprising six domiciliary face-to-face sessions and five telephone calls conducted by healthcare professionals and volunteers
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (no systematized intervention)
Number of subjects: 114
Study: 30929895

Group type: EXPERIMENTAL
Intervention: CT-P13
Number of subjects: 220

Group type: COMPARATOR
Intervention: Infliximab
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Both CT-P13 and Infliximab
Number of subjects: 220
Study: 28215494

Group type: EXPERIMENTAL
Intervention: 3D system
Number of subjects: 277

Group type: COMPARATOR
Intervention: 2D system
Number of subjects: 277
Study: 27352335

Group type: EXPERIMENTAL
Intervention: Retrograde autologous priming (RAP) for cardiopulmonary bypass (CPB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Crystal liquids priming (control)
Number of subjects: 0
Study: 23093468

Group type: EXPERIMENTAL
Intervention: Dangling procedure starting at day 3, with wrapping and dangling performed for 5 minutes three times a day, increasing to 60 minutes by day 5.
Number of subjects: 31

Group type: COMPARATOR
Intervention: Dangling procedure starting at day 7, with wrapping and dangling performed for 5 minutes three times a day, increasing to 60 minutes by day 5.
Number of subjects: 31
Study: 21330894

Group type: EXPERIMENTAL
Intervention: High-fidelity simulation
Number of subjects: 49

Group type: COMPARATOR
Intervention: Static simulation
Number of subjects: 49
Study: 19070758

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (20 mg/kg)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 73
Study: 16360143

Group type: EXPERIMENTAL
Intervention: Blood lead level (BLL) > 2.5 microg/dL
Number of subjects: 147

Group type: COMPARATOR
Intervention: Blood lead level (BLL) ≤ 2.5 microg/dL
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Mean blood lead level in infertile women
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Blood lead level as a predictor
Number of subjects: 147
Study: 15466632

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 0
Study: 11571241

Group type: EXPERIMENTAL
Intervention: Prior CABG
Number of subjects: 5410

Group type: COMPARATOR
Intervention: Patients without prior CABG
Number of subjects: 5410
Study: 9130194

Group type: EXPERIMENTAL
Intervention: Sexual abuse prevention program (2-hour curriculum)
Number of subjects: 431

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 431
Study: 8023802

Group type: EXPERIMENTAL
Intervention: Self-reported dietary habits and tobacco exposure assessment
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Use of supplements that did not contain carotene
Number of subjects: 203
Study: 2662802

Group type: EXPERIMENTAL
Intervention: 24 hours' recumbency
Number of subjects: 102

Group type: COMPARATOR
Intervention: 4 hours' recumbency
Number of subjects: 102
Study: 1181938

Group type: EXPERIMENTAL
Intervention: Behavioral modification approach
Number of subjects: 0
Study: 31860160

Group type: EXPERIMENTAL
Intervention: Anodal tDCS at 2.0-mA
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS at 2.0-mA
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 29
Study: 31289097

Group type: EXPERIMENTAL
Intervention: Counterclockwise intervention (1-week retreat, reliving younger selves in a retrofitted environment)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Active control group (same activities, no time manipulation)
Number of subjects: 90

Group type: COMPARATOR
Intervention: No-treatment group
Number of subjects: 90